A Phase 3 Multicenter Long-term Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type
J
Jared Brosch, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer's type.
Description
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer's type.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: - 100 Years
-
Gender: All
Updated on
18 Apr 2024.
Study ID: 1703611170
